The combination of SGLT2 inhibitors and GLP-1 receptor agonists has been suggested to provide additive effects in reducing oxidative stress, which could enhance vascular repair, thus mitigating vascular comorbidities linked to obesity and type 2 diabetes [198]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.